Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development

[1]  Hugo Geerts,et al.  Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response , 2012, PloS one.

[2]  Hugo Geerts,et al.  Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action , 2012, Alzheimer's Research & Therapy.

[3]  Birgit Schoeberl,et al.  An expanding role for cell biologists in drug discovery and pharmacology , 2012, Molecular biology of the cell.

[4]  E. D’Angelo.  The human brain project. , 2012, Functional neurology.

[5]  Urban Liebel,et al.  Behavioral barcoding in the cloud: embracing data-intensive digital phenotyping in neuropharmacology. , 2012, Trends in biotechnology.

[6]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[7]  H. Geerts,et al.  Failure analysis of dimebon using mechanistic disease modeling: Lessons for clinical development of new Alzheimer's disease therapies , 2012, Alzheimer's & Dementia.

[8]  P. Pizzo,et al.  The ER-mitochondria connection: New players in Alzheimer's disease , 2012, Alzheimer's & Dementia.

[9]  Hugo Geerts,et al.  A Quantitative Systems Pharmacology Computer Model for Schizophrenia Efficacy and Extrapyramidal Side Effects , 2012 .

[10]  Hugo Geerts,et al.  A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development , 2012, Journal of experimental pharmacology.

[11]  S. Kapur,et al.  Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. , 2011, The international journal of neuropsychopharmacology.

[12]  C. Halldin,et al.  Extrastriatal dopamine D2 receptor binding in Huntington's disease , 2011, Human brain mapping.

[13]  Vidhi Singh,et al.  Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia , 2011, CNS drugs.

[14]  D. Schoepp,et al.  Where will new neuroscience therapies come from? , 2011, Nature Reviews Drug Discovery.

[15]  M. Poo,et al.  Grand challenges in global mental health , 2011, Nature.

[16]  L. Redden,et al.  A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia , 2011, Journal of clinical psychopharmacology.

[17]  Hugo Geerts,et al.  Mechanistic disease modeling as a useful tool for improving CNS drug research and development , 2011 .

[18]  I. Bezprozvanny.  The rise and fall of Dimebon. , 2010, Drug News and Perspectives.

[19]  A. Hayashi‐Takagi,et al.  Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during neurodevelopment , 2010, Brain Research Bulletin.

[20]  Hugo Geerts,et al.  Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse , 2010, Neuropsychiatric disease and treatment.

[21]  E. Wong,et al.  The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. , 2010, Pharmacology & therapeutics.

[22]  H. Geerts,et al.  EXPLORING THE BIOLOGY OF ILOPERIDONE RESPONDER PROFILES IN TREATMENT OF SCHIZOPHRENIA USING A MECHANISTIC DISEASE MODEL , 2010, Schizophrenia Research.

[23]  S. Tkachenko,et al.  From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon. , 2010, Current Alzheimer research.

[24]  Kaori Ito,et al.  Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.

[25]  C. Bétry,et al.  Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation , 2009, Neuroscience Letters.

[26]  M. Polymeropoulos,et al.  Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study , 2009, Molecular Psychiatry.

[27]  S. Sherman,et al.  Over-expression of the potassium channel Kir2.3 using the dopamine-1 receptor promoter selectively inhibits striatal neurons , 2008, Neuroscience.

[28]  M. Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[29]  D. Casey,et al.  Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study , 2008, Psychopharmacology.

[30]  E. Schutter.  Why Are Computational Neuroscience and Systems Biology So Separate? , 2008, PLoS Comput. Biol..

[31]  B. Kolachana,et al.  COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET , 2008, Molecular Psychiatry.

[32]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[33]  J. Lieberman.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. , 2007, The Journal of clinical psychiatry.

[34]  C. Davies,et al.  Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. , 2006, European journal of pharmacology.

[35]  P Erdi,et al.  From systems biology to dynamical neuropharmacology: proposal for a new methodology. , 2006, Systems biology.

[36]  S. Kapur,et al.  From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.

[37]  J. Ryan,et al.  Translational research in central nervous system drug discovery , 2005, NeuroRX.

[38]  G. Laustsen,et al.  2004 drug approval highlights: FDA update. , 2005, The Nurse practitioner.

[39]  R. Palmiter,et al.  Dopamine Modulates Release from Corticostriatal Terminals , 2004, The Journal of Neuroscience.

[40]  J. Houk,et al.  Modulation of striatal single units by expected reward: a spiny neuron model displaying dopamine-induced bistability. , 2003, Journal of neurophysiology.

[41]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[42]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[43]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[44]  F Ivy Carroll,et al.  Concurrent Autoreceptor-Mediated Control of Dopamine Release and Uptake during Neurotransmission: An In Vivo Voltammetric Study , 2002, The Journal of Neuroscience.

[45]  E. Kuzhikandathil,et al.  Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. , 2002, Molecular pharmacology.

[46]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[47]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[48]  S. Cragg,et al.  Dopamine Release and Uptake Dynamics within Nonhuman Primate Striatum In Vitro , 2000, The Journal of Neuroscience.

[49]  J. Gorman,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Fabre,et al.  Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[51]  P. Mermelstein,et al.  Inwardly Rectifying Potassium (IRK) Currents Are Correlated with IRK Subunit Expression in Rat Nucleus Accumbens Medium Spiny Neurons , 1998, The Journal of Neuroscience.

[52]  E. Nisenbaum,et al.  Biophysical characterization and functional consequences of a slowly inactivating potassium current in neostriatal neurons. , 1998, Journal of neurophysiology.

[53]  M. Hines,et al.  The NEURON Simulation Environment , 1997, Neural Computation.

[54]  J. Bockaert,et al.  cAMP-dependent, long-lasting inhibition of a K+ current in mammalian neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[56]  H. Geerts,et al.  Not all partial dopamine D 2 receptor agonists are the same in treating schizophrenia. exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse , 2010 .

[57]  H. Geerts.  Bridging the Translational Disconnect in CNS Drug Discovery , 2009 .

[58]  T. de Paulis.  M-100907 (Aventis). , 2001, Current opinion in investigational drugs.

[59]  T. dePaulis.  M-100907 (Aventis). , 2001 .

[60]  L H Finkel,et al.  Neuroengineering models of brain disease. , 2000, Annual review of biomedical engineering.

[61]  R. Arya,et al.  Drug therapy , 2000 .

[62]  C. K. Hofling,et al.  Drug therapy. , 1967, Progress in neurology and psychiatry.